| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: 3 nM (FEN1), 226 nM (XPG)[1].
Flap endonuclease 1 (FEN1). FEN1-IN-2 is a selective and potent inhibitor of flap endonuclease 1 (FEN1), a key enzyme involved in DNA replication and repair. FEN1 plays a critical role in Okazaki fragment processing during DNA replication and in base excision repair. The compound inhibits FEN1 with an IC50 of 3 nM and also inhibits XPG with an IC50 of 226 nM. By blocking FEN1 activity, the compound disrupts DNA repair and replication processes. |
|---|---|
| ln Vitro |
FEN1-IN-2 inhibits FEN1 with an IC50 of 3 nM and XPG with an IC50 of 226 nM. By blocking FEN1 activity, the compound disrupts Okazaki fragment processing and base excision repair, leading to replication stress and DNA damage accumulation. The compound's ability to sensitize tumor cells to DNA-damaging agents makes it a valuable tool for oncology research and therapeutic strategy development.
|
| ln Vivo |
In vivo, FEN1-IN-2 has potential anticancer activity. By inhibiting FEN1 and disrupting DNA repair, the compound may sensitize tumor cells to DNA-damaging agents such as chemotherapy and radiation. As a research compound, it is used to study DNA repair pathways, replication fidelity, and synthetic lethality in cancer models. Further in vivo studies are needed to fully characterize its antitumor efficacy.
|
| Enzyme Assay |
Enzyme activity assays are used to measure the inhibitory activity of FEN1-IN-2 against FEN1 and XPG. Purified recombinant FEN1 or XPG enzymes are incubated with DNA substrates in the presence of increasing concentrations of the compound. Enzyme activity is measured by detecting cleavage products using gel electrophoresis or fluorescence-based assays. The reported IC50 values are 3 nM for FEN1 and 226 nM for XPG.
|
| Cell Assay |
Cellular assays using cancer cell lines are employed to evaluate the functional effects of FEN1-IN-2. Cells are treated with increasing concentrations of the compound (typically 0.1-100 μM) for various time points. DNA damage is assessed by measuring γ-H2AX foci formation, comet assays, or detecting DNA repair intermediates. Cell viability and proliferation are measured to determine the compound's antiproliferative effects. Combination studies with DNA-damaging agents can assess sensitization.
|
| Animal Protocol |
In vivo efficacy of FEN1-IN-2 has been evaluated in preclinical tumor models. The compound is typically administered orally or intraperitoneally, alone or in combination with DNA-damaging agents. Efficacy endpoints include tumor growth inhibition, survival, and assessment of DNA damage in tumor tissues. The compound's ability to sensitize tumors to chemotherapy or radiation is a key area of investigation.
|
| ADME/Pharmacokinetics |
As a small molecule with molecular weight of 393.41 g/mol and molecular formula C20H15N3O4S, FEN1-IN-2 is a selective FEN1 inhibitor. The compound is soluble in DMSO. Pharmacokinetic properties have not been fully characterized. The compound is stored at recommended conditions and is for research use only. Stability: ≥2 years under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data has been reported for FEN1-IN-2. As a DNA repair inhibitor, potential toxicities include effects on normal tissue with high proliferative rates. Standard toxicity assessments would include evaluation of cytotoxicity in normal cell lines, genotoxicity assays, and organ toxicity in animal models. The compound is for research use only and not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
FEN1-IN-2 (CAS#: 824983-94-0) is a selective and potent inhibitor of flap endonuclease 1 (FEN1), a key enzyme in DNA replication and repair. It inhibits FEN1 with an IC50 of 3 nM and XPG with an IC50 of 226 nM. By blocking FEN1 activity, the compound disrupts Okazaki fragment processing and base excision repair. FEN1-IN-2 has potential anticancer activity and is used to study DNA damage repair pathways. Molecular formula: C20H15N3O4S; molecular weight: 393.42. Purity: ≥95%.
|
| Molecular Formula |
C20H15N3O4S
|
|---|---|
| Molecular Weight |
393.42
|
| Exact Mass |
393.078
|
| CAS # |
824983-94-0
|
| PubChem CID |
11654052
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(=O)C2SC=CC=2N(CC2=CC(=CC=C2)C2=CC=C(C=C2)C(=O)N)C(N1O)=O
|
| InChi Key |
VQEJSOSSYFEKGH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H15N3O4S/c21-18(24)14-6-4-13(5-7-14)15-3-1-2-12(10-15)11-22-16-8-9-28-17(16)19(25)23(27)20(22)26/h1-10,27H,11H2,(H2,21,24)
|
| Chemical Name |
4-[3-[(3-hydroxy-2,4-dioxothieno[3,2-d]pyrimidin-1-yl)methyl]phenyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (254.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5418 mL | 12.7091 mL | 25.4181 mL | |
| 5 mM | 0.5084 mL | 2.5418 mL | 5.0836 mL | |
| 10 mM | 0.2542 mL | 1.2709 mL | 2.5418 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
